Keshu Zhou

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Jennifer R. Brown, Barbara Eichhorst, Peter Hillmen et al. · New England Journal of Medicine · 2022 · 457 citations · Full text

Medicine, Oncology, Pharmacology +16

Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

Yuqin Song, Keshu Zhou, Dehui Zou et al. · Clinical Cancer Research · 2020 · 183 citations

Medicine, Oncology, Pharmacology +17

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

Yuqin Song, Keshu Zhou, Dehui Zou et al. · Blood · 2022 · 169 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study

Wei Xu, Shenmiao Yang, Keshu Zhou et al. · Journal of Hematology & Oncology · 2020 · 129 citations · Full text

Medicine, Oncology, Pharmacology +15

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial

Peter Hillmen, Barbara Eichhorst, Jennifer R. Brown et al. · Journal of Clinical Oncology · 2022 · 93 citations · Full text

Medicine, Oncology, Pharmacology +15